Washington hasn't picked an interceptor for its homeland missile shield, but it's already writing billion-dollar checks for the eyes and brain that would run it.
Executive Order 14186 told the Pentagon to build a "Golden Dome for America" — a layered shield against ballistic, hypersonic, and cruise missiles. Congress backed it with $13.4 billion in the FY2026 defense appropriations bill, and the Pentagon now pegs the full architecture at $175–185 billion. But no interceptor has been selected, and the White House itself concedes the CBO's lifecycle estimate could run past $1 trillion. That timeline mismatch is the trade: you cannot intercept what you cannot see, so the government is funding detection, tracking, and command-and-control years before it funds a single kill vehicle. Money is already moving through that front door — the Space Development Agency's Tranche 3 Tracking Layer and Space Force space-domain-awareness buys are real, awarded contracts, not press-release vaporware.
Who cashes in:
You cannot intercept what you cannot see — so Washington is paying for the eyes and the brain years before it funds a single interceptor.
- Rocket Lab (RKLB) is the cleanest tracking-layer trade in the group. In December 2025 the SDA awarded $3.5 billion across four teams to build 72 Tranche 3 missile-tracking satellites — Rocket Lab's slice was $805 million for 18 space vehicles. Layer on the $90 million Space Force contract to build two GEO satellites hosting the Heimdall space-domain-awareness payload (via its Geost acquisition), and Rocket Lab is now a recurring vendor on both the "find the missile" and "watch the sky" halves of Golden Dome — before any interceptor contract exists.
- Palantir (PLTR) owns the brain, not the eyes. Reporting since March 2026 has Palantir teamed with Anduril on the command-and-control software meant to fuse radar, satellite, and sensor feeds into a single targeting picture for Golden Dome operators — the software layer every sensor above ultimately has to report into. Palantir has flagged Golden Dome as a phase-one revenue driver, and the stock has repeatedly re-rated on each new disclosure of scope.
- Leidos (LDOS) is the legacy plumbing bet: the company already runs missile-warning ground systems and space C2 integration work for the government, and a "system of systems" architecture needs an integrator gluing SDA, Space Force, and MDA data together — work that tends to land with incumbents who already hold the clearances and the ground infrastructure.
- Mercury Systems (MRCY) supplies the rad-hardened processing and RF hardware that goes inside sensor satellites and radars regardless of which prime wins the bus contract — a picks-and-shovels position underneath both Rocket Lab and its competitors.
Who is exposed:
- Kratos (KTOS) and AeroVironment (AVAV) are drone- and target-system-heavy; both would benefit eventually from a fielded Golden Dome, but their revenue is concentrated in aerial targets, munitions, and unmanned systems rather than the space-tracking and C2 dollars flowing right now — they're waiting on a program phase that hasn't started.
- Axon (AXON) has no real exposure to this mechanism at all; its Golden Dome "connection" in investor chatter is association-by-defense-sector, not contract flow, and treating it as a beneficiary confuses ticker-adjacency with cash.
The play: Track SDA and Space Systems Command award notices, not interceptor headlines — Tranche 3, Tranche 4, and follow-on SDA payload contracts are the near-term catalyst calendar, and they'll keep naming Rocket Lab, Palantir-adjacent primes, and legacy sensor integrators long before Congress or MDA picks a homeland interceptor architecture.
Source: original report ↗
Free alerts Free: catalyst alerts, straight to your inbox.
Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $40/mo Join the owners who run ahead of the industry. Cancel anytime, one click.